{
"ranked_hypotheses": [
{
"rank": 1,
"title": "ApoE-Isoform C1q Scaffold Hypothesis",
"mechanism": "ApoE isoforms serve as scaffolds that differentially modulate C1q deposition on lipid surfaces, altering complement activation patterns and microglial recognition.",
"target_gene": "APOE",
"confidence_score": 0.8,
"novelty_score": 0.5,
"feasibility_score": 0.6,
"impact_score": 0.8,
"composite_score": 0.68,
"testable_prediction": "SPR or co-immunoprecipitation assays comparing ApoE2/E3/E4 isoforms will reveal isoform-specific differences in C1q binding affinity to reconstituted lipid-ApoE complexes.",
"skeptic_concern": "Requires independent validation of the scaffold mechanism versus indirect effects, and clarification of whether ApoE-C1q binding is direct or lipid-mediated."
},
{
"rank": 2,
"title": "C1q-TREM2 Synaptic Pruning Ligand Hypothesis",
"mechanism": "C1q functions as an opsonin that facilitates microglial TREM2 recognition of disease-altered synapses through complement-tagged synaptic substrates.",
"target_gene": "TREM2",
"confidence_score": 0.7,
"novelty_score": 0.6,
"feasibility_score": 0.5,
"impact_score": 0.7,
"composite_score": 0.65,
"testable_prediction": "Co-culture of purified C1q with synapses followed by TREM2-Fc pulldown will demonstrate C1q-dependent bridging of synapses to TREM2-expressing microglia.",
"skeptic_concern": "Bridging requires physical proximity between C1q-bound synapses and TREM2; evidence for ternary complex formation on relevant surfaces is lacking."
},
{
"rank": 3,
"title": "Glyco-C1q Lectin Bridging Hypothesis",
"mechanism": "C1q binds directly to disease-altered glycans on myelin and synaptic membranes while simultaneously engaging microglial lectin receptors (SIGLEC3/CD33, CLEC7A), creating ternary complexes that modulate microglial activation.",
"target_gene": "C1QA",
"confidence_score": 0.5,
"novelty_score": 0.7,
"feasibility_score": 0.4,
"impact_score": 0.6,
"composite_score": 0.55,
"testable_prediction": "Glycan-array or SPR with purified C1q will demonstrate direct binding to AD-relevant sialylated/desialylated glycans and microglial lectin receptors.",
"skeptic_concern": "No validated lectin-binding domain exists on C1q; the hypothesized dual-domain architecture lacks structural support and requires fundamental validation."
}
],
"consensus_points": [
"Mechanistic studies on C1q-related hypotheses require prior independent validation using purified proteins and orthogonal binding assays",
"The fundamental premise that C1q directly engages microglial receptors has not been conclusively validated",
"Validation should establish whether observed effects are direct C1q-receptor interactions or indirect through surface-bound ligands"
],
"dissent_points": [
"Expert argues that translational potential justifies continued investigation despite mechanistic uncertainty, while Skeptic maintains that unvalidated premises risk wasted resources",
"Theorist believes glyco-C1q bridging offers a novel mechanism worth pursuing, while Skeptic challenges the foundational dual-domain assumption"
],
"debate_summary": "All parties agree that validation of C1q's direct interaction with microglial receptors remains essential before pursuing mechanism; the Skeptic's structural challenge regarding C1q's dual-domain architecture is unresolved, but the Expert identifies ApoE-C1q interactions as the most translationally promising pathway given existing evidence on both components."
}